Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
ABUS (Arbutus Biopharma) Financial Strength | news.google.com • |
Arbutus Biopharma (ABUS) to Release Quarterly Earnings on Thursday | news.google.com • |
Arbutus Biopharma (ABUS) to Release Earnings on Thursday | news.google.com • |
Moderna Investors Should Beware Patent-Dispute Fallout (NASDAQ:ABUS) | news.google.com • |
Trading Day Review: Arbutus Biopharma Corp (ABUS) Loses Momentum, Closing at 2.64 – DWinneX | news.google.com • |
ABUS (Arbutus Biopharma) Market Cap | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-02 | 2024-03 | -0.1 | N/A | N/A | N/A |
2024-02-29 | 2023-12 | -0.12 | -0.12 | N/A | N/A |
2023-11-07 | 2023-09 | -0.12 | -0.12 | N/A | N/A |
2023-08-03 | 2023-06 | -0.12 | -0.1 | 0.02 | 16.67% |
2023-05-04 | 2023-03 | -0.14 | -0.1 | 0.04 | 28.57% |
2023-03-02 | 2022-12 | -0.14 | -0.14 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-03 | Chardan Capital | Upgrade | Buy | Buy |
2023-07-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
2023-06-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-08-15 | ABRAMS MICHAEL J | Officer | 42.10K | Conversion of Exercise of derivative security |
2023-01-31 | COLLIER WILLIAM H. | Chief Executive Officer | 216.50K | Stock Award(Grant) |
2024-02-01 | HASTINGS DAVID C | Chief Financial Officer | 181.91K | Sale |
2023-01-31 | HOWARD ELIZABETH ANN | Officer | 86.02K | Stock Award(Grant) |
2024-02-01 | MC ELHAUGH MICHAEL JOHN | Chief Executive Officer | 1.50M | Sale |
2018-11-27 | MURRAY MARK J | Director | 341.40K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 9.97M | 22.93M | 5.95% |
2023-06-29 | Two Seas Capital Lp | 8.28M | 19.05M | 4.94% |
2023-06-29 | Whitefort Capital Management, LP | 8.09M | 18.62M | 4.83% |
2023-06-29 | Vanguard Group Inc | 5.82M | 13.38M | 3.47% |
2023-06-29 | Morgan Stanley | 5.08M | 11.68M | 3.03% |
2023-06-29 | Rubric Capital Management LP | 3.40M | 7.81M | 2.03% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.30M | 7.59M | 1.97% |
2023-08-30 | iShares Russell 2000 ETF | 2.73M | 5.54M | 1.63% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.61M | 3.70M | 0.96% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.09M | 2.37M | 0.65% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 861.37K | 1.75M | 0.51% |
2023-06-29 | Morgan Stanley Inst Fund Inc-Inception Port | 750.71K | 1.73M | 0.45% |
Split | Date |
---|---|
0.2 : 1 | 2010-11-04 |
-
Another tard
-
3.75 today
-
It’s such a casual part of the process... Do we even need to devote much funds as Moderna to create an LNP? It just magically appears. WTF you talking about?? Dear god.
-
Modernas LNP research division was set up when?
-
When is moderna gonna spin off their LNP division? Or when did they have funds going to that so called division??! Dear god.
-
Vaccines work. On the scale of 10’s of billions now given. Thank god for them. Boogie man = dumbfuck weirdos at this point
-
When the term “of from”” is used it is for a reason
-
Buqqets = tard Neither. Dear god. Dumbfucks still arguing reality. Billions of shots have been safely delivered. The recipients of the shots factually have super human immunity.
-
Ready for launch
-
Billions of shots delivered. Ill stick with the facts.
-
Ripe and ready for
-
I love them both
-
Ready for
-
Vivek is a tard.
-
Ready for launch
-
Moderna preemptively tried to invalidate patents and lost. So honest…
ARBUTUS = TARD
-
Moderna has warned of a "substantial risk" that Arbutus could invoke its '069 patent in an infringement suit targeting its COVID-19 vaccine
-
Bottom is in
-
Bottom is in
-
ABUS (Arbutus Biopharma) Financial Strength
news.google.com • -
Arbutus Biopharma (ABUS) to Release Quarterly Earnings on Thursday
news.google.com • -
Arbutus Biopharma (ABUS) to Release Earnings on Thursday
news.google.com • -
Moderna Investors Should Beware Patent-Dispute Fallout (NASDAQ:ABUS)
news.google.com • -
ABUS (Arbutus Biopharma) Market Cap
news.google.com • -
Arbutus to Participate in Two Upcoming Investor Conferences
globenewswire.com • -
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Arbutus to Present at Jefferies London Healthcare Conference
globenewswire.com • -
3 Stocks to Buy For the COVID Resurgence
marketbeat.com • -
Arbutus to Participate in Two Upcoming Investor Conferences
globenewswire.com • -
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
globenewswire.com • -
Arbutus to Present at Jefferies Healthcare Conference
globenewswire.com • -
Arbutus (ABUS) Upgraded to Buy: Here's Why
zacks.com • -
Arbutus to Present at JMP Securities Life Sciences Conference
globenewswire.com • -
Arbutus Biopharma clinical hold slows hepatitis B momentum: broker
proactiveinvestors.com • -
Why Arbutus Biopharma Stock Is Sinking Today
fool.com • -
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
globenewswire.com • -
Arbutus to Participate in Three Upcoming Investor Conferences
globenewswire.com • -
Arbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Arbutus to Present at Jefferies London Healthcare Conference
globenewswire.com • -
Arbutus to Present at Chardan's 6th Annual Genetic Medicines Conference
globenewswire.com • -
Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
seekingalpha.com • -
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
seekingalpha.com • -
Arbutus to Participate in June Investor Conferences
globenewswire.com • -
Arbutus, Genevant sue Moderna, citing patent infringement
marketwatch.com • -
4 Penny Stocks To Buy For Under $5 With Unusual Options Activity
pennystocks.com • -
What's the Outlook for Arbutus Biopharma?
fool.com • -
Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
globenewswire.com • -
Roivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy Arbutus
seekingalpha.com • -
Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?
seekingalpha.com • -
Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets
pennystocks.com • -
Why Arbutus Biopharma Shares Are Rising
benzinga.com • -
Got $5 to Spend on Penny Stocks? Check These 4 Out
pennystocks.com • -
4 Penny Stocks That Are Trending on Reddit Right Now and Why
pennystocks.com • -
5 Penny Stocks To Buy According To Analysts & Targets Up To 341%
pennystocks.com • -
Why Arbutus Shares Are Soaring Today
benzinga.com • -
5 Short Squeeze Penny Stocks To Watch For November 2021
pennystocks.com • -
Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
pennystocks.com • -
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
pennystocks.com • -
Arbutus to Participate in October Investor Conferences
globenewswire.com • -
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
globenewswire.com • -
ABUS Stock: Why It Increased This Week
pulse2.com • -
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
globenewswire.com • -
Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist
pennystocks.com •